UBS Maintains a 'Buy' on Watson Pharmaceuticals (WPI); Solid 4Q10; Eyes on Concerta & Prochieve
Tweet Send to a Friend
UBS maintains a 'Buy' on Watson Pharmaceuticals (NYSE: WPI), raises PT from $59 to $64.
UBS analyst says, "What we ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
UBS analyst says, "What we ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
